# US 11,028,092 B2 · Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,028,092 B2
- Document ID: US11028092B2
- Status: Granted
- Kind: B2
- Application number: 16/670,093
- Filed: 2019-10-31
- Published: 2020-05-07
- Granted: 2021-06-08
- Earliest claimed: 2017-06-08
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Ashok Arasappan; Jason M. Cox; John S. Debenham; Zahid Hussain; Derun Li; Dongfang Meng; Subharekha Raghavan
- Web page: https://patentgrep.com/patent/US11028092B2

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to pyrazolopyrimidine compounds of the general structural formula I: which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

## Claims

### Claim 1

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The compound of claim 2, wherein the compound is:

### Claim 4 (depends on 2)

The compound of claim 2, wherein the compound is a pharmaceutically acceptable salt of:

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The compound of claim 5, wherein the compound is:

### Claim 7 (depends on 5)

The compound of claim 5, wherein the compound is a pharmaceutically acceptable salt of:

### Claim 8 (depends on 1)

The compound of claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 8)

The compound of claim 8, wherein the compound is:

### Claim 10 (depends on 8)

The compound of claim 8, wherein the compound is a pharmaceutically acceptable salt of:

### Claim 11 (depends on 1)

The compound of claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

The compound of claim 11, wherein the compound is:

### Claim 13 (depends on 11)

The compound of claim 11, wherein the compound is a pharmaceutically acceptable salt of:

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 14)

The compound of claim 14, wherein the compound is:

### Claim 16 (depends on 14)

The compound of claim 14, wherein the compound is a pharmaceutically acceptable salt of:

### Claim 17 (depends on 1)

The compound of claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The compound of claim 17, wherein the compound is:

### Claim 19 (depends on 17)

The compound of claim 17, wherein the compound is a pharmaceutically acceptable salt of:

### Claim 20 (depends on 1)

A pharmaceutical composition comprising an inert carrier and a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

A method for inhibiting phosphodiesterase 9 activity in a mammalian patient, comprising administering to the mammalian patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein the mammalian patient has a disease or disorder associated with phosphodiesterase 9 dysfunction.

### Claim 23 (depends on 22)

The method of claim 22, wherein the disease or disorder associated with phosphodiesterase 9 dysfunction is selected from the group consisting of heart failure, hypertension, a cardiovascular disease, a cerebrovascular disease, and a chronic kidney disease.

### Claim 24 (depends on 22)

The method of claim 22, wherein the disease or disorder associated with phosphodiesterase 9 dysfunction is selected from the group consisting of drug induced psychosis, an anxiety disorder, a delusional disorder, a movement disorder, a neurological disorder, and a psychotic disorder.